World At Net · Health & Science · Longevity Series
Can Humans Live Beyond 120 Years?
Science is redrawing the outer edge of human life. The question is no longer only how long we can live, but how well. (Replace with commissioned artwork using the featured image prompt above before publishing.)
Executive Summary
For decades, 122 years stood as the known ceiling of human life, the age reached by Jeanne Calment of France before her death in 1997 and never verified in anyone since. That number is now being challenged from two directions at once. In July 2026, researchers at the Skolkovo Institute of Science and Technology in Russia published a mathematical model in the journal npj Aging suggesting that even if science eliminated every other driver of aging, irreversible damage to DNA in cells that do not regenerate, particularly in the brain and heart, would still cap human life somewhere between 150 and 190 years, with a median estimate near 156. At the same time, a fast growing field called geroscience is treating aging itself as a treatable process, targeting twelve identified biological hallmarks with senolytic drugs, partial cellular reprogramming, and metabolic therapies that have already shown measurable results in early human trials. This article walks through where the science actually stands, separates the proven from the speculative, examines what the Blue Zones can and cannot teach us, and asks what any of this means for a country like Pakistan, where average life expectancy still sits near 68 years and the basic infrastructure for elder care remains thin.
Article Snapshot
Key Highlights
- A 2026 mathematical model out of Russia is the first to propose a specific biological reason, rather than a statistical guess, for why human life may top out well short of forever.
- Aging researchers now describe the process through twelve interacting hallmarks rather than a single cause, which is why no single pill is likely to unlock radical life extension.
- Senolytic drugs that clear aged, dysfunctional cells have shown real reductions in inflammation and improved mobility in elderly trial participants, not just in laboratory animals.
- The five validated Blue Zones keep producing centenarians at unusual rates, and new research suggests psychological traits such as stress response and curiosity matter alongside diet.
- Roughly twenty percent of how long a person lives is attributable to genetics, according to long running twin studies, which leaves a large share open to environment and behavior.
- Pakistan's population aged 65 and above is growing quickly even as the health system remains largely unprepared for chronic, long term geriatric care.
Quick Facts
- The global population aged 65 and older is projected to roughly double, from about 761 million in 2021 to around 1.6 billion within two to three decades.
- Five Blue Zones have been independently validated: Sardinia in Italy, Okinawa in Japan, Nicoya in Costa Rica, Ikaria in Greece, and the Seventh Day Adventist community of Loma Linda in California, alongside Martinique.
- A 2025 to 2026 wave of clinical trials is testing combination therapies, such as rapamycin paired with hormone therapy, rather than single interventions.
- Healthy life expectancy in Pakistan, the years lived in good health rather than simply alive, is estimated at just under 57 years, well below the 68 year figure for life expectancy at birth.
Table of Contents
- What We Actually Mean by the 120 Year Question
- The Twelve Hallmarks of Aging
- The 2026 Model: Why Somatic Mutations May Be the True Ceiling
- Jeanne Calment and the Verified Human Record
- Inside the Blue Zones: Fact, Nuance, and Controversy
- The Geroscience Toolkit: Senolytics, Reprogramming, and Rapamycin
- Genes Versus Environment: How Much Control Do We Have?
- Healthspan Versus Lifespan
- The Business of Immortality: Billionaires and Biotech
- Ethics, Inequality, and the Politics of a Longer Life
- Pakistan and South Asia in an Aging World
- What the Next Twenty Years Are Likely to Bring
Chapter 1: What We Actually Mean by the 120 Year Question
When people ask whether humans can live beyond 120, they are usually mixing together three very different questions. The first is a statistical one: what is the oldest age a human has ever verifiably reached. The second is biological: is there a hard ceiling built into our cells that no medicine can move. The third is practical: could ordinary people, not outliers, realistically expect to live meaningfully longer than today's average. Longevity science increasingly treats these as separate problems with separate answers, and conflating them is where most popular coverage goes wrong.
The number 120 itself has folkloric roots. It appears in religious and cultural texts across traditions as a symbolic outer limit of a human life, long before any biologist attempted to measure it. Modern gerontology inherited the figure almost by coincidence, since the best documented human life, that of Jeanne Calment, landed at 122, close enough to the old symbolic number to reinforce it in the public imagination. What has changed in 2026 is that researchers now have a mechanistic argument, not just an observed record, for roughly where a true biological ceiling might sit.
Did You Know?
The oldest living person recognized by Guinness World Records in 2026 is Ethel Caterham of the United Kingdom, at 116 years old, six years short of Calment's confirmed record.
Chapter 2: The Twelve Hallmarks of Aging
Modern aging research is organized around a framework known as the hallmarks of aging, a set of interconnected biological processes that, taken together, describe why bodies decline over time. The list has grown from an original nine to twelve as research has matured, and current work groups them into three tiers.
Primary hallmarks, the root damage
These include genomic instability, the gradual accumulation of DNA damage; telomere attrition, the shortening of protective caps on chromosomes with each cell division; epigenetic alterations, changes in how genes are switched on and off without altering the underlying DNA sequence; and loss of proteostasis, the breakdown of the cell's ability to fold and dispose of proteins correctly.
Antagonistic hallmarks, the body's flawed compensations
These are responses that help in the short term but cause harm if they persist, including cellular senescence, where damaged cells stop dividing but refuse to die and instead release inflammatory signals; mitochondrial dysfunction, the decline of the cell's energy producing structures; and deregulated nutrient sensing, the disruption of pathways that govern metabolism and growth.
Integrative hallmarks, the visible consequences
These are the outcomes that eventually produce disease and frailty: stem cell exhaustion, which limits the body's capacity to repair tissue; altered intercellular communication, including chronic low grade inflammation sometimes called inflammaging; disabled macroautophagy, the loss of the cell's internal cleanup system; and chronic inflammation itself as a distinct, compounding driver.
Key Takeaway
Because aging results from at least twelve interacting mechanisms, most serious researchers now expect meaningful life extension to come from combination therapies that target several hallmarks at once, not from a single miracle compound.
| Tier | Hallmark | Plain Language Meaning |
|---|---|---|
| Primary damage | Genomic instability | DNA mutations build up over a lifetime |
| Telomere attrition | Chromosome end caps wear down | |
| Epigenetic alterations | Gene switches drift out of their youthful pattern | |
| Loss of proteostasis | Cells struggle to manage proteins correctly | |
| Compensatory response | Cellular senescence | Damaged cells linger and emit inflammatory signals |
| Mitochondrial dysfunction | Cellular energy production declines | |
| Deregulated nutrient sensing | Metabolic control pathways go off balance | |
| Downstream consequence | Stem cell exhaustion | Tissue repair capacity shrinks |
| Altered intercellular communication | Cells send confused or harmful signals to each other | |
| Disabled macroautophagy | Cellular waste disposal slows | |
| Chronic inflammation | Low grade inflammation persists and compounds damage |
Chapter 3: The 2026 Model, Why Somatic Mutations May Be the True Ceiling
In July 2026, researchers Evgeniy Efimov, Vlad Fedotov, and Leonid Malaev, working at the Skolkovo Institute of Science and Technology, published a paper in npj Aging that approached the ceiling question differently from prior work. Rather than extrapolating from historical mortality statistics, the team built a mathematical model of somatic mutation accumulation, the DNA damage that builds up in cells throughout life due to environmental exposure and errors in copying, and asked a narrower question: if every other cause of aging were somehow solved, how long could a person live before this one mechanism alone became fatal.
The model first imagined a person who experienced no age related increase in mortality risk at all, an unrealistic baseline under which projected median lifespan reached 1,759 years. The researchers then reintroduced a single variable, somatic mutations, and the projected median lifespan collapsed to 156 years. The organs identified as the hardest constraint were the brain and the heart, because their cells largely do not regenerate, so DNA damage there cannot be replaced the way it can in tissues such as skin or the gut lining that continuously renew themselves. Broader simulations from the same research group suggested a plausible range of roughly 150 to 190 years under this specific mechanism.
It is important to be precise about what this study does and does not claim. It does not assert that 156 years is an absolute physical impossibility to exceed, and the authors themselves note that future breakthroughs in DNA repair or tissue regeneration could change the picture. Nor does it offer any treatment that could extend life toward that number. What it offers is a mechanistic reason, grounded in cell biology rather than statistical curve fitting, for why a ceiling somewhere in that range is plausible under current scientific understanding.
Did You Know?
The 156 year figure came from comparing two versions of the same model: one with no aging related mortality at all, projecting over 1,700 years of median survival, and one where only DNA damage in non regenerating cells was added back in.
Chapter 4: Jeanne Calment and the Verified Human Record
Jeanne Louise Calment, born in Arles, France, in 1875, remains the only human being whose lifespan of 122 years and 164 days has withstood rigorous demographic verification, including birth records, family documentation, and repeated independent audits after her death in 1997. For years her age was treated by demographers as close to a natural species limit, an idea reinforced by a widely cited 2016 study in the journal Nature that argued human lifespan had plateaued near 115 years for the general population, with Calment as a rare outlier.
The current record for a living person belongs to Ethel Caterham of the United Kingdom, recognized by Guinness World Records at 116 years old in 2026. The gap between the current oldest living person and Calment's historical record is itself informative: it shows that reaching the very outer edge of the known human range remains exceptionally rare even now, decades after Calment's death, despite widespread improvements in medicine, nutrition, and sanitation across wealthy countries.
Chapter 5: Inside the Blue Zones, Fact, Nuance, and Controversy
The term Blue Zones was coined roughly two decades ago to describe regions with an unusually high concentration of people who reach very old age in reasonably good health. Five such regions have been identified and independently validated: Sardinia in Italy, Okinawa in Japan, Nicoya in Costa Rica, Ikaria in Greece, and Martinique, a French overseas territory, with the Seventh Day Adventist community of Loma Linda, California often included as a sixth.
The concept has faced sustained scientific scrutiny, mostly over whether self reported and poorly documented ages in some regions were reliable. A study published in the journal The Gerontologist in late 2025 and amplified through early 2026 re-examined the underlying demographic data and concluded that several of the original Blue Zones hold up under independent analysis, even as some peripheral claims about newer or less studied regions do not. At the same time, prominent researchers and science journalists have pushed back publicly, arguing that the term has been stretched far beyond its original, narrowly defined scientific basis by wellness marketing. The honest summary is that the core five regions have real, defensible longevity data behind them, while some later additions to the Blue Zones brand deserve more skepticism.
What actually explains the pattern remains debated. Long running research by Blue Zones founder Dan Buettner points to a set of shared lifestyle factors nicknamed the Power 9, an approach to longevity that emphasizes environment and social structure over any single diet or supplement, built on the finding from Danish twin studies that only about twenty percent of longevity is attributable to genetics. More recent work has pushed further. A 2026 study from Sardinia's Blue Zone compared 125 adults aged 71 to 101, half from the Blue Zone itself and half from a nearby but demographically similar rural area, and found that psychological traits such as how people respond to stress, remain curious, and stay engaged with daily life may matter as much as diet and physical activity.
Chapter 6: The Geroscience Toolkit, Senolytics, Reprogramming, and Rapamycin
Where the Blue Zones represent an observational, lifestyle based approach to longevity, a separate and increasingly well funded field called geroscience is attempting to intervene directly in the biological hallmarks described earlier. Several categories of intervention have moved from animal studies into human trials over the past two years.
Senolytics
Senolytic compounds are designed to selectively clear senescent cells, the damaged cells that refuse to die and instead spew inflammatory signals into surrounding tissue. The record here is more mixed than early coverage often suggests. An independent 2026 review of the senolytics pipeline found that Unity Biotechnology's intra-articular candidate for knee osteoarthritis, UBX0101, failed to outperform placebo on pain in a randomized trial, while the same company's locally delivered eye therapy for diabetic macular edema produced statistically meaningful results in later stage trials. The pattern across the field is consistent: senolytics look most promising where a drug is delivered directly into an accessible, diseased tissue, such as the eye or skin, and considerably less proven as a systemic anti aging treatment.
Rapamycin and metabolic drugs
Long term, low dose rapamycin studies running through 2025 and into 2026 continue to show encouraging safety and biomarker results, and researchers are increasingly testing it alongside other therapies rather than alone, an approach that mirrors combination treatment models already standard in oncology and cardiology. Metformin, a decades old diabetes drug, remains under investigation for broader anti aging effects, though results in non diabetic populations are still preliminary.
Partial cellular reprogramming
Using a set of proteins known as Yamanaka factors, researchers are experimenting with partially resetting the epigenetic age of cells without erasing their identity entirely, an approach still largely confined to laboratory and early animal work but advancing quickly with the help of AI assisted compound discovery.
Stem cell and regenerative approaches
Stem cell therapies are increasingly discussed as a bridge between lifespan, how long a person lives, and healthspan, how long they live well. Regulatory shifts in several U.S. states during 2025 and 2026 have begun to give patients more direct access to certain autologous stem cell treatments for orthopedic and pain applications, under new manufacturing and safety standards, though rigorous, large scale evidence of anti aging benefit specifically remains limited outside of a handful of well studied conditions such as knee osteoarthritis.
What Early Human Trial Data Shows, 2025 to 2026
Bars are illustrative proportions for editorial comparison, not to a single common scale. See References for underlying sources.
Chapter 7: Genes Versus Environment, How Much Control Do We Have?
Danish twin study research, a foundation for much of modern longevity science, established that approximately twenty percent of how long a person lives is dictated by genetics, leaving a substantial majority of the outcome open to environment, behavior, and circumstance. This finding is central to why researchers increasingly resist purely genetic or purely pharmaceutical explanations for exceptional longevity, and why lifestyle focused research on the Blue Zones has retained scientific relevance even as some of its edges have been challenged.
That said, genetics still matters at the extremes. Rare genetic variants affecting DNA repair efficiency, lipid metabolism, and inflammatory response are disproportionately common among centenarians and supercentenarians, suggesting that reaching the very outer tail of the human lifespan distribution likely requires a combination of favorable genetics and favorable environment, rather than either alone.
Chapter 8: Healthspan Versus Lifespan
A distinction that has become central to serious longevity research is the difference between lifespan, simply how many years a person is alive, and healthspan, how many of those years are spent free of significant disability or chronic disease. Extending lifespan without extending healthspan risks simply prolonging the period of frailty at the end of life, an outcome most researchers and most people would not consider a genuine win.
The gap between the two is stark in real populations. In Pakistan, healthy life expectancy, the years lived in full health, is estimated at just under 57 years, more than a decade below the roughly 68 year life expectancy at birth figure, meaning the average Pakistani spends over a decade of life managing chronic illness or disability before death. Closing that gap, rather than simply pushing the outer number higher, is where most public health experts argue the real near term opportunity lies.
Key Takeaway
For almost everyone alive today, the more consequential longevity question is not whether science can eventually push the ceiling to 150 years, but whether it can shrink the number of unhealthy years most people currently spend near the end of life.
Chapter 9: The Business of Immortality, Billionaires and Biotech
Well funded initiatives including Altos Labs, Calico, and Retro Biosciences, backed respectively by figures including Jeff Bezos and OpenAI's Sam Altman, have deployed several billion dollars combined into geroscience research at a scale that would have been unimaginable a decade ago. The picture is not uniformly rosy, however: 2025 also saw notable setbacks, including Unity Biotechnology's closure after its senolytic programs failed to deliver a clear clinical win. Consumer facing longevity protocols vary enormously in price, from subscription supplement and testing programs costing a few hundred dollars a month to experimental clinical interventions costing tens of thousands of dollars or more, and industry observers expect costs to fall as the underlying technologies mature and scale, though that remains a projection rather than an established trend.
This commercial acceleration cuts two ways. It has genuinely sped up the translation of laboratory findings into human trials, which is why several therapies discussed in this article have moved from animal models to real patient data within just the past two to three years. It has also raised concerns among researchers that the field risks fragmenting into competing, non complementary private efforts rather than a coordinated scientific discipline, a tension that public health institutions and regulators are still working out.
Chapter 10: Ethics, Inequality, and the Politics of a Longer Life
Anticipatory science bodies tracking the field describe radical health extension as an opportunity that carries a real risk of becoming a new axis of global inequality rather than a shared human benefit, unless deliberately designed to reach populations beyond the wealthy few who can currently afford advanced clinical protocols. The concern is straightforward: if extended, high quality lifespan becomes available primarily to those who can pay tens of thousands of dollars for treatment, the gap between rich and poor nations, and between rich and poor individuals within the same nation, could widen in a dimension, years of healthy life itself, that has never before been directly for sale.
There are also unresolved policy questions that longevity science will force societies to confront regardless of how fast the underlying biology advances: retirement age and pension design in a world where working life could plausibly extend into the eighties or nineties, generational turnover in leadership and property ownership, and healthcare systems built around the assumption of a certain average lifespan suddenly facing a different distribution of need.
Chapter 11: Pakistan Perspective, Aging in a Young Country
Pakistan's relationship with the longevity question looks very different from that of wealthy longevity research hubs in the United States, Europe, or East Asia. Average life expectancy at birth in the country sits at roughly 68 years in 2026, with a notable gap between men, around 66 years, and women, around 71 years, and the country ranks near 151st out of 197 nations globally on this measure. Healthy life expectancy is considerably lower still, estimated at just under 57 years combined, meaning the average Pakistani citizen lives more than a decade with significant illness or disability before death.
Pakistan remains a demographically young country, with only about 4.2 percent of the population aged 65 or above as of recent counts, compared with much higher shares in aging societies such as Japan or several European nations. But that share is rising, and the country's health infrastructure has not kept pace. A recent analysis published in the Pakistan Armed Forces Medical Journal describes a geriatric health system that is fundamentally unprepared, noting that older Pakistanis frequently carry multiple chronic conditions such as hypertension, diabetes, heart disease, and joint pain simultaneously, while mental health conditions including depression, anxiety, and dementia in the elderly remain widely under-recognized and under-treated. The same analysis points to overcrowded hospitals, a weak primary care layer, and a severe shortage of physicians specifically trained in geriatric medicine as structural barriers to adequate elder care.
The gap between what advanced longevity science is beginning to offer in wealthy countries and what most elderly Pakistanis can access is therefore not a distant, hypothetical future inequality. It already exists today, in the more basic form of unequal access to routine geriatric care, chronic disease management, and mental health services for the aging population Pakistan already has. Any national conversation about longevity science needs to start there, with strengthening primary and geriatric healthcare, before it moves on to the more speculative frontier of senolytics and partial reprogramming discussed elsewhere in this article.
Expert Insight
Public health researchers focused on South Asia consistently make a similar point: for a country at Pakistan's stage of demographic transition, the highest return longevity investment is not cutting edge biotechnology but strengthening primary care, expanding geriatric medical training, and building chronic disease management infrastructure capable of catching hypertension, diabetes, and cardiovascular disease before they compound into disability.
Chapter 12: What the Next Twenty Years Are Likely to Bring
Stripping away speculation, a reasonably grounded forecast for the next two decades looks something like this. Industry voices in the longevity field commonly cite adding 10 to 20 additional healthy years as an achievable goal within 15 to 20 years, driven primarily by combination therapies targeting several hallmarks of aging simultaneously rather than any single breakthrough drug. Independent academic reviewers are more cautious. A 2025 analysis in the journal Biogerontology concludes that, given the long lag between laboratory discovery and clinical translation and the limited number of interventions proven to reliably extend lifespan in animal studies, increases of ten or more years to average human lifespan in developed countries are unlikely to be imminent, even though aging itself is clearly modifiable to some degree. Senolytics and metabolic interventions such as rapamycin are likely to move from experimental to mainstream clinical use for specific, localized age related conditions well before any therapy targeting maximum lifespan itself gains approval. Routine biological age testing is expected to become progressively more common in wealthier health systems, even as it remains largely inaccessible in much of the developing world for years longer.
The theoretical ceiling identified by the 2026 somatic mutation model, meanwhile, is unlikely to be approached by anyone alive today. It functions less as a near term target and more as a signpost, showing researchers exactly where the hardest remaining problem sits: repairing or replacing DNA damage in the brain and heart, organs whose cells largely do not regenerate on their own. Progress against that specific problem, more than any wellness trend or supplement, will be the real marker to watch for anyone tracking whether the outer edge of human life is actually moving.
Longevity Science Timeline
Jeanne Calment lives 122 years and 164 days, a record that still stands as the only fully verified case beyond 120.
Blue Zones concept emerges from field research in Sardinia, later extended to Okinawa, Nicoya, Ikaria, Loma Linda, and Martinique.
The original hallmarks of aging framework is published, organizing gerontology around a defined set of biological mechanisms rather than a single theory.
A widely cited study proposes a natural human lifespan plateau near 115 years, intensifying debate over whether Calment was a true outlier.
Senolytic and partial reprogramming research accelerates, moving from animal studies toward early human trials, aided by AI assisted drug discovery.
Independent demographic review in The Gerontologist reaffirms the validity of the core Blue Zones longevity data after years of public scrutiny.
Skolkovo Institute researchers publish a model in npj Aging proposing a 150 to 190 year theoretical ceiling driven by somatic mutation accumulation in non regenerating organs.
Key Numbers at a Glance
At a Glance: Longevity Approaches Compared
| Approach | Mechanism Targeted | Current Evidence Level | Accessibility Today |
|---|---|---|---|
| Blue Zones lifestyle model | Diet, movement, purpose, social structure | Strong observational, decades of data | Free, universally applicable |
| Rapamycin, low dose | Nutrient sensing pathway (mTOR) | Promising, ongoing long term human trials | Off label, physician dependent, limited outside major markets |
| Senolytics | Clearance of senescent cells | Positive early human trial data for specific conditions | Experimental, largely trial or specialty clinic access |
| Partial cellular reprogramming | Epigenetic age reset (Yamanaka factors) | Early stage, mostly animal and lab data | Not clinically available |
| Metformin (off label anti aging use) | Metabolic and nutrient signaling | Mixed, long safety record for diabetes, less clear for healthy adults | Prescription required, inexpensive where approved |
| Stem cell and regenerative therapy | Tissue repair, stem cell exhaustion | Growing, condition specific evidence | Expensive, regulatory status varies widely by country |
Glossary
- Senescent cell
- A cell that has stopped dividing due to damage or age but does not die, and instead releases inflammatory signals into surrounding tissue.
- Senolytic
- A class of compounds designed to selectively identify and clear senescent cells from the body.
- Somatic mutation
- A DNA change that occurs in body cells during a person's lifetime, as opposed to mutations inherited at birth, which accumulates due to environmental exposure and replication errors.
- Healthspan
- The portion of a person's life spent free of significant chronic disease or disability, distinct from total lifespan.
- Hallmarks of aging
- A set of twelve interconnected biological mechanisms, including genomic instability, cellular senescence, and mitochondrial dysfunction, that together drive the aging process.
- Yamanaka factors
- A set of four proteins that can reprogram mature cells toward a more youthful state, named after Nobel laureate Shinya Yamanaka.
- Blue Zone
- A geographically defined region with a demographically validated, unusually high concentration of people reaching age 90 or 100 in relatively good health.
- Geroscience
- The interdisciplinary scientific field studying the biological mechanisms of aging with the goal of preventing or delaying age related disease.
Future Outlook
The most likely trajectory over the coming generation is not a dramatic leap to 150 year lifespans, but a steady compression of the unhealthy years most people currently endure at the end of life, paired with modest, incremental gains in the outer limit itself. Expect biological age testing, senolytic therapy for specific conditions, and combination metabolic treatments to move from research settings into mainstream clinical practice in wealthy health systems within the next decade, while the deeper question of repairing DNA damage in non regenerating organs, the true frontier identified by the 2026 model, remains a multi decade scientific challenge. For countries such as Pakistan, the more urgent and more solvable near term outlook is closing the healthspan gap through stronger primary and geriatric care, rather than waiting on frontier biotechnology that will likely remain financially out of reach for most of the population for years to come.
Frequently Asked Questions
Is 156 years now the confirmed maximum human lifespan?
No. It is a theoretical ceiling proposed by a 2026 mathematical model based on one specific mechanism, DNA damage in non regenerating organs. It is not a confirmed limit, and the authors themselves note future scientific advances could change the estimate.
Who is the oldest person alive today?
As of 2026, Ethel Caterham of the United Kingdom, recognized by Guinness World Records at 116 years old, holds the title.
Are Blue Zones scientifically real, or just a marketing concept?
The five original regions have held up under independent demographic review published in late 2025, though the broader Blue Zones brand has expanded well beyond the original, more rigorously studied areas, and some newer claims deserve more scrutiny.
Can ordinary people access senolytics or rapamycin for anti aging purposes today?
Not in any officially approved form for healthy aging in most countries, including Pakistan. These remain experimental or off label uses requiring physician oversight, and this article does not constitute medical advice or a recommendation to pursue them.
How much of longevity is genetic?
Long running twin studies attribute roughly twenty percent of longevity to genetics, leaving the larger share open to environment, healthcare access, and lifestyle.
What does this mean practically for someone living in Pakistan today?
The most relevant near term lever is not frontier biotechnology but closing the gap between life expectancy and healthy life expectancy, roughly eleven years in Pakistan currently, through better management of hypertension, diabetes, and cardiovascular disease, and through stronger geriatric care infrastructure.
Related World At Net Articles
References
- Efimov, E., Fedotov, V., Malaev, L., and Kriukov, D. (2026). Somatic mutation modeling and the theoretical limits of human lifespan. npj Aging. https://doi.org/10.1038/s41514-026-00421-6
- ScienceAlert. (2026, July 22). Ultimate limit of the human lifespan may be identified, study suggests.
- Upworthy. (2026, July 21). Science thought the human lifespan was 122 years. A new model says we could live decades longer.
- Guinness World Records. (2026). Oldest person living: Ethel Caterham.
- Buettner, D. (2025). Lessons from the Blue Zones: There is no silver bullet for a long, healthy life. American Journal of Lifestyle Medicine.
- Austad, S. N., and Pes, G. M. (2025, December 17). The validity of Blue Zones demography: A response to critiques. The Gerontologist.
- Wood, S., and Topol, E. (2026, May 4). Are blue zones real? Answering that question is harder than ever. STAT News.
- mindbodygreen. (2026, July 23). Blue Zone centenarians share this overlooked trait, new study finds.
- Longevity Next. (2026, March; updated July). The senolytics pipeline in 2026: Where the science still looks strong, and where it doesn't.
- Contrary Research. (2026, May). Retro Biosciences business breakdown and founding story.
- GESDA Global. (2025, December 4). Radar spotlight: Longevity science crosses the clinical threshold.
- Ho, J. Y., et al. (2025). Realistic expectations for changes to average human lifespan in the near future. Biogerontology.
- United Nations. (2024). World Population Prospects 2024.
- georank.org. (2026, July 8). Pakistan: Life expectancy 1950-2026 and calculator by age, based on UN World Population Prospects.
- Pakistan Armed Forces Medical Journal. (2026, February 28). Geriatric health in Pakistan: A crisis we are not ready for.
Editor's Note. Longevity science moves quickly, and figures such as the theoretical lifespan ceiling discussed in this piece are drawn from a single 2026 modeling study, not an established consensus. World At Net will revisit this topic as new peer reviewed research emerges, particularly on DNA repair therapies targeting the brain and heart. Readers are encouraged to treat specific numbers here as current best estimates rather than fixed facts, and to consult qualified medical professionals before acting on any health related information.
Conclusion
The honest answer to whether humans can live beyond 120 years is that a handful already have, one verified case beyond it entirely, and that the real frontier question has shifted from whether such ages are possible to whether they are desirable, equitable, and biologically achievable at scale. The 2026 somatic mutation model gives science its clearest mechanistic reason yet for where a true ceiling might sit, somewhere well north of 120 but almost certainly short of true immortality, bounded by the stubborn biology of organs that do not regenerate. Meanwhile, the more consequential story for most of the eight billion people alive today, especially in countries like Pakistan where healthy life expectancy still lags life expectancy by more than a decade, is not the distant question of a 150 year lifespan. It is the far more immediate and far more solvable question of whether ordinary people can be given a fair shot at the healthy years already biologically available to them.
World At Net · Health & Science · Global Perspectives for a Changing World
0 Comments